noscapine and Triple-Negative-Breast-Neoplasms

noscapine has been researched along with Triple-Negative-Breast-Neoplasms* in 3 studies

Other Studies

3 other study(ies) available for noscapine and Triple-Negative-Breast-Neoplasms

ArticleYear
9-PAN promotes tubulin- and ROS-mediated cell death in human triple-negative breast cancer cells.
    The Journal of pharmacy and pharmacology, 2020, Volume: 72, Issue:11

    To examine the antiproliferative effect of a rationally designed, novel noscapine analogue, 9-((perfluorophenyl)methylene) aminonoscapine, '9-PAN') on MDA-MB-231 breast cancer cell line, and to elucidate the underlying mechanism of action.. The rationally designed Schiff base-containing compound, 9-PAN, was characterized using IR, NMR and mass spectra analysis. The effect of the compound on cell viability was studied using an MTT assay. Cell cycle and cell death analyses were performed using flow cytometry. Binding interactions of 9-PAN with tubulin were studied using spectrofluorometry. Reactive oxygen species (ROS) generation and mitochondrial membrane potential (MMP) were investigated using the probes, DCFDA and rhodamine-123, respectively. Immunofluorescence imaging was used to visualize cellular microtubules.. 9-PAN exerts its antiproliferative effect by targeting tubulin and elevating ROS level in the cells.

    Topics: Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Design; Female; G2 Phase Cell Cycle Checkpoints; Humans; Membrane Potential, Mitochondrial; Mitochondria; Noscapine; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Triple Negative Breast Neoplasms; Tubulin; Tubulin Modulators

2020
Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.
    Scientific reports, 2017, Nov-20, Volume: 7, Issue:1

    Multidrug resistance (MDR) is a major impediment to cancer treatment. Here, for the first time, we investigated the chemo-sensitizing effect of Noscapine (Nos) at low concentrations in conjunction with docetaxel (DTX) to overcome drug resistance of triple negative breast cancer (TNBC). In vitro experiments showed that Nos significantly inhibited proliferation of TNBC wild type (p < 0.01) and drug resistant (p < 0.05) TNBC cells. Nos followed by DTX treatment notably increased the cell viability (~1.3 fold) markedly (p < 0.05) in 3D models compared to conventional 2D systems. In vivo oral administration of Nos (100 mg/kg) followed by intravenous DTX (5 mg/kg) liposome treatment revealed regression of xenograft tumors in both wild type (p < 0.001) and drug-resistant (p < 0.05) xenografts. In wild type xenografts, combination of Nos plus DTX group showed 5.49 and 3.25 fold reduction in tumor volume compared to Nos and DTX alone groups, respectively. In drug-resistant xenografts, tumor volume was decreased 2.33 and 1.41 fold in xenografts treated with Nos plus DTX significantly (p < 0.05) compared to Nos and DTX alone respectively and downregulated the expression of anti-apoptotic factors and multidrug resistance proteins. Collectively, chemo-sensitizing effect of Nos followed by DTX regime provide a promising chemotherapeutic strategy and its significant role for the treatment of drug-resistant TNBC.

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Mice; Noscapine; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2017
Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
    Experimental cell research, 2016, 08-01, Volume: 346, Issue:1

    Chemosensitization and enhanced delivery to solid tumor are widely explored strategies to augment the anticancer efficacy of existing chemotherapeutics agents. The aim of current research was to investigate the role of low dose Noscapine (Nos) in potentiating docetaxel cytotoxicity and enhancing tumor penetration of nanocarriers. The objectives are; (1) To evaluate the chemo-sensitizing effect of Nos in combination with docetaxel (DTX), and to elucidate the possible mechanism (2) To investigate the effect of low dose Nos on tumor stroma and enhancing nanocarrier uptake in triple negative breast cancer (TNBC) bearing nude mice. Cytotoxicity and flow cytometry analysis of DTX in Nos (4µM) pre-treated MDA-MB-231 cells showed 3.0-fold increase in cell killing and 30% increase in number of late apoptotic cells, respectively. Stress transducer p38 phosphorylation was significantly upregulated with Nos exposure. DTX showed remarkable downregulation in expression of bcl-2, survivin and pAKT in Nos pre-treated MDA-MB-231 cells. Nos pre-sensitization significantly (p<0.02) enhanced the anti-migration effect of DTX. In vivo studies in orthotopic TNBC tumor bearing mice showed marked reduction in tumor collagen-I levels and significantly (p<0.03) higher intra-tumoral uptake of coumarin-6 loaded PEGylated liposomes (7-fold) in Nos treated group. Chemo-sensitization and anti-fibrotic effect of Nos could be a promising approach to increase anticancer efficacy of DTX which can be used for other nanomedicinal products.

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Coumarins; Docetaxel; Drug Carriers; Enzyme Activation; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Liposomes; Mice; Microtubules; Nanoparticles; Noscapine; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Polymerization; Staining and Labeling; Taxoids; Thiazoles; Triple Negative Breast Neoplasms; Tubulin; Xenograft Model Antitumor Assays

2016